Lung function measures and acetylcholinesterase in each project phase
| Phase 1 (Sept/Oct 2018) | Phase 2 (Nov/Dec 2018) | Phase 3 (Jan/Feb 2019) | Δ/phase | |
| FEV1 (L) | 2.36 (1.94 to 2.88) | 2.33 (1.92 to 2.78) | 2.28 (1.91 to 2.81) | −0.04 (−0.05 to −0.03) |
| n | 290 | 285 | 263 | |
| FVC (L) | 2.82 (2.36 to 3.47) | 2.83 (2.33 to 3.41) | 2.77 (2.37 to 3.41) | −0.03 (−0.04 to −0.01) |
| n | 288 | 285 | 263 | |
| FEV1/FVC | 0.83 (0.80 to 0.87) | 0.83 (0.79 to 0.87) | 0.83 (0.79 to 0.87) | −0.01 (−0.01 to −0.00) |
| n | 288 | 285 | 263 | |
| PEF (L/s) | 6.01 (5.06 to 7.40) | 6.15 (5.21 to 7.41) | 5.93 (5.22 to 7.31) | 0.01 (−0.04 to 0.07) |
| n | 290 | 285 | 263 | |
| FEF25 (L/s) | 5.08 (4.04 to 5.99) | 4.96 (3.97 to 5.90) | 4.94 (3.89 to 5.90) | −0.05 (−0.11 to 0.01) |
| n | 290 | 285 | 263 | |
| FEF50 (L/s) | 3.18 (2.30 to 3.73) | 2.94 (2.19 to 3.71) | 2.94 (2.16 to 3.72) | −0.09 (−0.13 to −0.06) |
| n | 290 | 285 | 263 | |
| FEF75 (L/s) | 0.95 (0.70 to 1.33) | 0.93 (0.66 to 1.25) | 0.90 (0.64 to 1.27) | −0.04 (−0.06 to −0.02) |
| n | 290 | 285 | 263 | |
| FEF25-75 (L/s) | 2.47 (1.82 to 3.13) | 2.35 (1.73 to 3.05) | 2.35 (1.67 to 3.02) | −0.07 (−0.10 to −0.04) |
| n | 290 | 285 | 263 | |
| FEV1 Z-score | −0.155 (−0.750 to 0.405) | −0.220 (−0.802 to 0.356) | −0.315 (−0.893 to 0.229) | −0.10 (−0.13 to −0.07) |
| n | 290 | 285 | 263 | |
| FVC Z-score | −0.257 (−0.850 to 0.387) | −0.307 (−0.798 to 0.297) | −0.342 (−0.933 to 0.196) | −0.06 (−0.09 to −0.03) |
| n | 288 | 285 | 263 | |
| FEV1/FVC Z-score | 0.127 (−0.402 to 0.793) | 0.142 (−0.511 to 0.757) | 0.119 (−0.491 to 0.744) | −0.08 (−0.13 to −0.03) |
| n | 288 | 285 | 263 | |
| FEF25-75 Z-score | −0.234 (−0.780 to 0.419) | −0.227 (−0.777 to 0.294) | −0.306 (−0.882 to 0.341) | −0.07 (−0.11 to −0.04) |
| n | 290 | 285 | 263 | |
| AChE (U/mL) | 3.10 (2.74 to 3.48) | 2.98 (2.63 to 3.31) | 2.88 (2.54 to 3.22) | −0.12 (−0.14 to −0.10) |
| n | 364 | 353 | 354 | |
| Hb (g/dL) | 11.80 (11.10 to 12.70) | 11.50 (10.60 to 12.20) | 11.70 (10.80 to 12.40) | −0.13 (−0.18 to −0.07) |
| n | 364 | 353 | 354 | |
| AChE/Hb (U/g) | 26.30 (23.90 to 28.10) | 26.20 (23.70 to 28.40) | 24.70 (22.30 to 27.20) | −0.74 (−0.85 to −0.63) |
| n | 364 | 353 | 354 |
All variables are presented as median (IQR). Z-scores and FEV1/FVC are unitless. Δ/phase denotes the mean change in the variable when phase increases by 1. CIs for Δ/phase was calculated in a mixed effect model with random effects for family and person, and fixed effect for phase.
AChE/Hb, erythrocyte acetylcholinesterase normalised by haemoglobin concentration.